Ireland - English - HPRA (Health Products Regulatory Authority)

genthon b.v. - pemetrexed - concentrate for solution for infusion - 25 milligram(s)/millilitre - folic acid analogues; pemetrexed

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france (s.a.s). - pemetrexed (pemetrexed disodium heptahydrate) - powder for concentrate for solution for infusion - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - pemetrexed - powder for concentrate for solution for infusion - 100 milligram(s) - folic acid analogues; pemetrexed

Ireland - English - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - pemetrexed - powder for concentrate for solution for infusion - 500 milligram(s) - folic acid analogues; pemetrexed

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pemetrexed - concentrate for solution for infusion - 25 milligram(s)/millilitre - folic acid analogues; pemetrexed

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eastern pharma co (epc), saudi arabia - pemetrexed - powder for solution for infusion - 100 mg,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eastern pharma co (epc), saudi arabia - pemetrexed - powder for solution for infusion - 500 mg,

Singapore - English - HSA (Health Sciences Authority)

mylan pharmaceuticals pte. ltd. - pemetrexed disodium 551.424mg eqv pemetrexed - injection, powder, lyophilized, for solution - 500mg - pemetrexed disodium 551.424mg eqv pemetrexed 500mg

United Kingdom - English - myHealthbox

caduceus pharma ltd. - pemetrexed - concentrate for solution for infusion - 25mg - folic acid analogues - malignant pleural mesothelioma pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - pemetrexed - mesothelioma; carcinoma, non-small-cell lung - antineoplastic agents - malignant pleural mesotheliomaalimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.non-small-cell lung canceralimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.